RFK, Jr.’s Overhauled Autism Advisory Board Cancels First Public Meeting

Why It Matters

The shift threatens the credibility and direction of federally funded autism research, potentially steering resources toward politically driven agendas rather than evidence‑based science.

Key Takeaways

• IACC meeting postponed after RFK Jr.'s board overhaul
• 21 new members include known vaccine skeptics
• Independent Autism Coordinating Committee convenes same day
• Scientists warn misinformation undermines autism research
• Federal autism funding direction now uncertain

Pulse Analysis

The Interagency Autism Coordinating Committee has long served as the federal nexus for setting autism research priorities, meeting quarterly to advise agencies such as HHS, NIH, and CDC. In January, Secretary Robert F. Kennedy Jr. executed a sweeping personnel change, appointing 21 new members—some with public stances that reject the established link between vaccines and autism. This dramatic reshaping raised alarms among researchers who fear that policy recommendations could become entangled with ideology, potentially diverting funding away from rigorously vetted studies.

Concurrently, a coalition of autism experts launched the Independent Autism Coordinating Committee, convening on the same day the IACC was slated to meet. Comprising former federal advisers and leading scientists, the I‑ACC positions itself as a corrective mechanism to address what its members describe as "damage" inflicted by the new federal board. Their formation underscores a growing trend of parallel advisory structures emerging to fill perceived gaps left by the federal government, especially after the Trump era’s retreat from coordinated public‑health initiatives. This parallelism could fragment the research agenda, creating competing narratives that complicate grant allocations and policy formulation.

The broader implications extend beyond a single meeting cancellation. As federal guidance on autism research becomes contested, stakeholders—from advocacy groups to biotech firms—must navigate an increasingly politicized landscape. Ensuring that research funding remains anchored in peer‑reviewed evidence is critical for maintaining scientific integrity and public trust. Policymakers, therefore, face pressure to balance political appointments with the need for expertise, lest the United States lose its leadership in autism science and compromise outcomes for the autistic community.